Completed PHASE1 INTERVENTIONAL 2-arm NCT06166992

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

Investigation of Pharmacokinetics and Absolute Oral Bioavailability of BI 1291583 Administered as an Oral Dose With an Intravenous Microtracer Dose of [14C]-BI 1291583 in Healthy Male Volunteers

Sponsor: Boehringer Ingelheim

Conditions Healthy

Interventions BI 1291583 [14C]-BI 1291583

Updated 6 times since 2024 Last updated: Aug 8, 2025 Started: Dec 12, 2023 Primary completion: Feb 7, 2024 Completion: Feb 7, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Boehringer Ingelheim leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2024 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1

First recorded

Dec 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Groningen, Netherlands